The United States faces the potential loss of its global biotechnology leadership position to China within the next two years, according to testimony delivered by Biotechnology Innovation Organization CEO John Crowley. GeoVax Labs, Inc. responded to this warning by calling for immediate congressional and administrative action to secure America's competitiveness and biosecurity through strategic investments and policy reforms.
David A. Dodd, Chairman and CEO of GeoVax, emphasized the urgency of the situation, stating that competitiveness in biotechnology represents a critical national security issue. The company outlined six priority actions needed from policymakers to address the growing threat to American biotech dominance. These include diversifying vaccine platforms beyond current reliance on mRNA technology by funding alternative approaches such as MVA and other multi-antigen, next-generation technologies.
The recommendations also call for onshoring advanced manufacturing capabilities with continuous cell-line vaccine production and U.S.-based fill/finish capacity. Protecting National Institutes of Health funding that fuels the biotech innovation pipeline represents another crucial element of the proposed strategy. Modernizing Food and Drug Administration pathways through expanded use of immuno-bridging and expedited programs for high-risk populations would accelerate development timelines.
GeoVax highlighted the need to expand incentives such as priority review vouchers for biodefense products while pairing China guardrails with domestic U.S. investment to ensure scale-up and resilience at home. The company pointed to two near-term solutions already in development that could immediately strengthen national security. Their GEO-MVA Mpox/smallpox vaccine, targeted to be manufactured on a continuous cell line, could position the U.S. with a critical supply source to replenish the Strategic National Stockpile and address global demand shortfalls.
The company's GEO-CM04S1 multi-antigen COVID-19 vaccine represents another immediate opportunity, designed specifically for immunocompromised individuals who remain vulnerable despite current vaccine options. Dodd emphasized that these are not distant concepts but programs ready for implementation now. The GEO-MVA vaccine can immediately strengthen national security by adding a U.S. supplier for the stockpile, while the CM04S1 vaccine addresses the needs of more than 40 million immunocompromised Americans who continue to face elevated risks.
The warning comes at a critical juncture for American biotechnology leadership, with global competition intensifying and supply chain vulnerabilities exposed by recent public health crises. The potential loss of biotech dominance carries significant implications for national security, economic competitiveness, and public health preparedness. By acting promptly on these recommendations, policymakers could transform current warnings into substantive wins for both public health and continued U.S. leadership in the global biotechnology landscape. For additional information about current clinical trials and program updates, visit https://www.geovax.com.
